BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 20126829)

  • 1. A small-molecule inhibitor of integrin alpha2 beta1 introduces a new strategy for antithrombotic therapy.
    Nissinen L; Pentikäinen OT; Jouppila A; Käpylä J; Ojala M; Nieminen J; Lipsanen A; Lappalainen H; Eckes B; Johnson MS; Lassila R; Marjamäki A; Heino J
    Thromb Haemost; 2010 Feb; 103(2):387-97. PubMed ID: 20126829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-glycoprotein VI treatment severely compromises hemostasis in mice with reduced alpha2beta1 levels or concomitant aspirin therapy.
    Grüner S; Prostredna M; Aktas B; Moers A; Schulte V; Krieg T; Offermanns S; Eckes B; Nieswandt B
    Circulation; 2004 Nov; 110(18):2946-51. PubMed ID: 15505105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel α2β1 integrin inhibitors reveal that integrin binding to collagen under shear stress conditions does not require receptor preactivation.
    Nissinen L; Koivunen J; Käpylä J; Salmela M; Nieminen J; Jokinen J; Sipilä K; Pihlavisto M; Pentikäinen OT; Marjamäki A; Heino J
    J Biol Chem; 2012 Dec; 287(53):44694-702. PubMed ID: 23132859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of the interactions between collagen and its receptors on platelets.
    Deckmyn H; De Meyer SF; Broos K; Vanhoorelbeke K
    Handb Exp Pharmacol; 2012; (210):311-37. PubMed ID: 22918737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of murine integrin alpha2beta1 in thrombus stabilization and embolization: contribution of thromboxane A2.
    Kuijpers MJ; Pozgajova M; Cosemans JM; Munnix IC; Eckes B; Nieswandt B; Heemskerk JW
    Thromb Haemost; 2007 Nov; 98(5):1072-80. PubMed ID: 18000613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of thrombosis and enhancement of thrombolysis in rabbits by SR 121787, a glycoprotein II/III antagonist.
    Hoffmann P; Bernat A; Savi P; Herbert JM
    J Pharmacol Exp Ther; 1998 Aug; 286(2):670-5. PubMed ID: 9694919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of PD0348292, a selective factor Xa inhibitor, to antiplatelet agents for the inhibition of arterial thrombosis.
    Karnicki K; Leadley RJ; Baxi S; Peterson T; Wysokinski W; McBane RD
    Thromb Haemost; 2008 Apr; 99(4):759-66. PubMed ID: 18392334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Principal role of glycoprotein VI in alpha2beta1 and alphaIIbbeta3 activation during collagen-induced thrombus formation.
    Lecut C; Schoolmeester A; Kuijpers MJ; Broers JL; van Zandvoort MA; Vanhoorelbeke K; Deckmyn H; Jandrot-Perrus M; Heemskerk JW
    Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1727-33. PubMed ID: 15231520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis.
    Vilahur G; Casaní L; Badimon L
    Thromb Haemost; 2007 Sep; 98(3):662-9. PubMed ID: 17849057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition.
    Freund M; Mantz F; Nicolini P; Gachet C; Mulvihill J; Meyer L; Beretz A; Cazenave JP
    Thromb Haemost; 1993 May; 69(5):515-21. PubMed ID: 8322274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet deposition induced by severely damaged vessel wall is inhibited by a boroarginine synthetic peptide with antithrombin activity.
    Badimon JJ; Weng D; Chesebro JH; Fuster V; Badimon L
    Thromb Haemost; 1994 Apr; 71(4):511-6. PubMed ID: 8052972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of a novel and potent collagen antagonist, caffeic acid phenethyl ester, in human platelets: in vitro and in vivo studies.
    Hsiao G; Lee JJ; Lin KH; Shen CH; Fong TH; Chou DS; Sheu JR
    Cardiovasc Res; 2007 Sep; 75(4):782-92. PubMed ID: 17560560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
    Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different regions of the class P-III snake venom metalloproteinase jararhagin are involved in binding to alpha2beta1 integrin and collagen.
    Tanjoni I; Evangelista K; Della-Casa MS; Butera D; Magalhães GS; Baldo C; Clissa PB; Fernandes I; Eble J; Moura-da-Silva AM
    Toxicon; 2010 Jun; 55(6):1093-9. PubMed ID: 20056118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis.
    Schrör K
    Semin Thromb Hemost; 1997; 23(4):349-56. PubMed ID: 9263351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The alpha2beta1 integrin inhibitor rhodocetin binds to the A-domain of the integrin alpha2 subunit proximal to the collagen-binding site.
    Eble JA; Tuckwell DS
    Biochem J; 2003 Nov; 376(Pt 1):77-85. PubMed ID: 12871211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical roles for the actin cytoskeleton and cdc42 in regulating platelet integrin alpha2beta1.
    Pula G; Poole AW
    Platelets; 2008 May; 19(3):199-210. PubMed ID: 18432521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Inactivated factor VII exercises a powerful antithrombotic activity in an experimental model of recurrent arterial thrombosis].
    Ragni M; Golino P; Cirillo P; Pascucci I; Scognamiglio A; Ravera A; Esposito N; Battaglia C; Guarino A; Chiariello M
    Cardiologia; 1996 Jan; 41(1):51-8. PubMed ID: 8697470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.
    Penz SM; Reininger AJ; Toth O; Deckmyn H; Brandl R; Siess W
    Thromb Haemost; 2007 Mar; 97(3):435-43. PubMed ID: 17334511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-thrombotic effects and bleeding risk of AJvW-2, a monoclonal antibody against human von Willebrand factor.
    Kageyama S; Yamamoto H; Nagano M; Arisaka H; Kayahara T; Yoshimoto R
    Br J Pharmacol; 1997 Sep; 122(1):165-71. PubMed ID: 9298543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.